Baseline and early changes in circulating Serum Amyloid A (SAA) predict survival outcomes in advanced non-small cell lung cancer patients treated with Anti-PD-1/PD-L1 monotherapy.

Authors:

Li-Na He Sha Fu Xuanye Zhang Qiaozhen Hu Wei Du Haifeng Li Tao Chen Chen Chen Yongluo Jiang Yixin Zhou Zuan Lin Yunpeng Yang Yan Huang Hongyun Zhao Wenfeng Fang Li Zhang Shaodong Hong

Lung Cancer 2021 08 28;158:1-8. Epub 2021 May 28.

State Key Laboratory of Oncology in South China, Guangzhou, China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China. Electronic address:

Background: Systemic inflammation plays an important role in carcinogenesis and is associated with overall survival in patients with different cancer types, including those treated with immune checkpoint blockade (ICB). Serum Amyloid A (SAA) is an acute-phase protein and a marker of persistent inflammation. We hypothesized that circulating SAA may predict outcomes in advanced non-small cell lung (aNSCLC) patients treated with PD-1/PD-L1 ICB.

Materials And Methods: This retrospective study included 91 aNSCLC patients who received anti-PD-(L)1 monotherapy in Sun Yat-sen University Cancer Center (Guangzhou, China) between August 2016 and June 2018. We examined the impact of circulating SAA at baseline and 8 (±2) weeks later on overall survival (OS). X-tile program was used to determine the cut-off values which optimized the significance of the split between Kaplan-Meier survival curves. Kaplan-Meier methodology and Cox regression analyses were conducted for survival analyses.

Results: The optimal cut-off value of baseline SAA for OS stratification was 137.6 mg/L. In univariate analysis, both high level of baseline SAA (hazard ratio [HR], 2.76; 95% confidence interval [CI], 1.47-5.18; P = 0.002) and lack of early SAA descent (HR, 1.51; 95% CI, 1.11-2.06; P = 0.009) were significantly associated with inferior OS. In multivariate analysis, gender, smoking status, performance status, liver metastasis, neutrophil-to-lymphocyte ratio, baseline SAA and early changes in SAA independently predicted OS (all with P < 0.05). A combined baseline SAA ≥ 137.6 mg/L and without early SAA descent identified a small cohort with remarkably worse OS (median, 3.2 months).

Conclusions: Both high baseline and lack of early decline in circulating SAA are significantly associated with inferior outcomes in aNSCLC patients treated with PD-1/PD-L1 ICB. Combined these two SAA indexes provided improved risk stratification. The prognostic value of this simple, readily-available, and cost-effective biomarker warrants larger, prospective validation before definitive recommendation can be made.

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.lungcan.2021.05.030	DOI Listing

August 2021

Publication Analysis

Top Keywords

Keyword Occurance

Similar Publications

Efficacy of a loading dose of IV salbutamol in children with severe acute asthma admitted to a PICU: a randomized controlled trial.

Authors:

Shelley A Boeschoten Corinne M P Buysse Brenda C M de Winter Joost van Rosmalen Johan C de Jongste Rogier C de Jonge Sabien G J Heisterkamp Job B van Woensel Martin C J Kneyber Annelies van Zwol Annemie L M Boehmer Matthijs de Hoog

Eur J Pediatr 2022 Aug 3. Epub 2022 Aug 3.

Department of Pediatric Surgery & Intensive Care, Erasmus MC - Sophia Children's Hospital, University Medical Center Rotterdam, Rotterdam, the Netherlands.

The optimal dose regimen for intravenous (IV) treatment in children with severe acute asthma (SAA) is still a matter of debate. We assessed the efficacy of adding a salbutamol loading dose to continuous infusion with salbutamol in children admitted to a pediatric intensive care unit (PICU) with SAA. This multicentre, placebo-controlled randomized trial in the PICUs of four tertiary care children's hospitals included children (2-18 years) with SAA admitted between 2017 and 2019. Read More

View Article and Full-Text PDF

August 2022

Similar Publications

High-Dose Rifampicin Mediated Systemic Alterations of Cytokines, Chemokines, Growth Factors, Microbial Translocation Markers, and Acute-Phase Proteins in Pulmonary Tuberculosis.

Authors:

Gokul Raj Kathamuthu Perumal Kannabiran Bhavani Manjula Singh Jitendra Kumar Saini Ashutosh Aggarwal Mohammed Soheb S Ansari Rajiv Garg Subash Babu

Front Pharmacol 2022 15;13:896551. Epub 2022 Jul 15.

National Institutes of Health-NIRT-International Center for Excellence in Research, Chennai, India.

High-dose rifampicin (HDR) is now undergoing clinical trials to improve the efficacy of anti-tuberculosis treatment (ATT). However, the influence of HDR in the modulation of different cytokines, chemokines/growth factors, microbial translocation markers (MTMs), and acute-phase proteins (APPs) in pulmonary tuberculosis (PTB) is not well known. PTB individuals were separated into three different arms (R10, R25, and R35) based on their rifampicin dosage. Read More

View Article and Full-Text PDF

July 2022

Similar Publications

Physiological stress reactivity in pediatric cancer survivors treated with chemotherapy.

Authors:

Gillian W White Shawn G Rhind Paul C Nathan Jessica E Caterini Heather Np Jones Greg D Wells

Pediatr Blood Cancer 2022 Jul 26:e29881. Epub 2022 Jul 26.

Translational Medicine Program, The Hospital for Sick Children, Toronto, Canada.

Children who experience early life stress demonstrate changes to their stress responses, which may modulate long-term health. Childhood cancer presents significant stress during diagnosis, treatment, and survivorship. We hypothesized that children who have completed chemotherapy treatment for ALL will demonstrate altered hormone patterns in response to a stressor compared with healthy controls. Read More

View Article and Full-Text PDF

July 2022

Similar Publications

Predicting Response of Severe Aplastic Anemia to Rabbit-Antithymocyte Immunoglobulin Based Immunosuppressive Therapy Combined With Eltrombopag.

Authors:

Ruixin Li Jiongtao Zhou Zhengyuan Liu Xi Chen Qiqiang Long Yan Yang Shengyun Lin Jinsong Jia Guangsheng He JianYong Li

Front Immunol 2022 26;13:884312. Epub 2022 May 26.

Department of Hematology, The First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing, China.

Addition of eltrombopag (E-PAG) to intensive immunosuppressive therapy (IST) contributes to restoring hematopoiesis in patients with severe aplastic anemia (SAA). Used at relatively low doses in the East Asian population, the efficacies of E-PAG and the predictors for efficacy are not clear. We conducted a retrospective, multicenter study to analyze the efficacy and the possible predicting factors at 6 months in 58 adult SAA patients with rabbit ATG-based IST and E-PAG. Read More

View Article and Full-Text PDF

June 2022

Similar Publications

Evaluating immune response and metabolic related biomarkers pre-allogenic hematopoietic stem cell transplant in acute myeloid leukemia.

Authors:

Sharareh Siamakpour-Reihani Felicia Cao Jing Lyu Yi Ren Andrew B Nixon Jichun Xie Amy T Bush Mark D Starr James R Bain Michael J Muehlbauer Olga Ilkayeva Virginia Byers Kraus Janet L Huebner Nelson J Chao Anthony D Sung

PLoS One 2022 14;17(6):e0268963. Epub 2022 Jun 14.

Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, North Carolina, United States of America.

Although hematopoietic stem cell transplantation (HCT) is the only curative treatment for acute myeloid leukemia (AML), it is associated with significant treatment related morbidity and mortality. There is great need for predictive biomarkers associated with overall survival (OS) and clinical outcomes. We hypothesized that circulating metabolic, inflammatory, and immune molecules have potential as predictive biomarkers for AML patients who receive HCT treatment. Read More

View Article and Full-Text PDF

June 2022

Similar Publications

}

Search Our Scientific Publications & Authors